Page 42 - Hal Barron News Today : Breaking News, Live Updates & Top Stories | Vimarsana

GSK’s PD-1 inhibitor dostarlimab shows updated promise in dMMR solid tumours Investigational PD-1 inhibitor is being studied in mismatch repair-deficient solid tumours GlaxoSmithKline’s (GSK) dostarlimab – an investigational PD-1 inhibitor – has demonstrated promising results in patients with heavily pre-treated solid cancer tumours. The updated data comes from cohort F of GSK's GARNET trial, which enrolled patients with mismatch repair-deficient (dMMR) non-endometrial advanced solid cancer tumours. The majority of this cohort had gastrointestinal cancer, with the highest prevalence ...

Second Vir-GSK monoclonal antibody to enter Phase 1/2 COVID-19 trials Vir Biotechnology and GSK will evaluate VIR-7832 in the early treatment of COVID-19 in a Phase 1b/2a trial starting in the first quarter of this year. Preclinical data suggests VIR-7832, a neutralising COVID-19 antibody, has two distinguishing properties: an enhanced ability to clear infected cells and the potential to enhance virus-specific T cell function, which could help treat and/or prevent COVID-19 infection. California’s Vir Biotechnology and GSK entered into a coronavirus collaboration ...

One of Britain’s biggest drugs companies said yesterday that it had more than ten potential blockbuster treatments in the late stages of development.Hal Barron, chief scientific officer and head of

GlaxoSmithKline (GSK), along with Vir Biotechnology, has agreed with the UK-based AGILE initiative to assess VIR-7832 in patients with Covid-19

On a day of major developments, Glaxosmithkline said it was joining an NHS study to test a breakthrough antibody treatment. The drug - known as Vir-7832 -could be a game changer.